# OnCo record cutaneous-t-cell-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/cutaneous-t-cell-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "cutaneous-t-cell-lymphoma" ;
  schema:name "Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)"@en ;
  schema:alternateName "CTCL"@en, "Mycosis fungoides"@en, "Sezary syndrome"@en ;
  schema:description "Cutaneous T-cell lymphoma is a family of nine lymphomas that start in the skin and mostly stay there, of which mycosis fungoides is by far the commonest. Most of them are long-term skin conditions managed over decades rather than cancers that are cured or not cured, and two of the nine are genuinely aggressive."@en ;
  schema:url <https://onco.cc/cancers/cutaneous-t-cell-lymphoma/> ;
  schema:dateModified "2026-09-29"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Mycosis_fungoides> ;
  schema:citation <https://en.wikipedia.org/wiki/Mycosis_fungoides>, <https://doi.org/10.1038/s41375-022-01620-2>, <https://doi.org/10.1182/blood.2022015851>, <https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq>, <https://lymphoma-action.org.uk/types-lymphoma>, <https://doi.org/10.1038/bjc.2015.94> ;
  onco:tag "subtype-page" ;
  onco:related <https://onco.cc/cancers/peripheral-t-cell-lymphoma/>, <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/biomarkers/ig-tcr-clonality/>, <https://onco.cc/cancers/mycosis-fungoides/>, <https://onco.cc/cancers/sezary-syndrome/>, <https://onco.cc/cancers/lymphomatoid-papulosis/>, <https://onco.cc/cancers/primary-cutaneous-anaplastic-large-cell-lymphoma/>, <https://onco.cc/cancers/primary-cutaneous-marginal-zone-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/clonality-testing/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/technologies/histopathology-ihc/> ;
  onco:targets <https://onco.cc/targets/ccr4/>, <https://onco.cc/targets/cd52/>, <https://onco.cc/targets/cd30/>, <https://onco.cc/targets/stat3/>, <https://onco.cc/targets/stat5/>, <https://onco.cc/targets/jak3/> ;
  onco:drugs <https://onco.cc/drugs/hypericin-sgx301/> ;
  onco:pathways <https://onco.cc/pathways/jak-stat/>, <https://onco.cc/pathways/tumor-microenvironment/> ;
  onco:terms <https://onco.cc/terms/lymphoma-bio-lineage-antigen-cost/>, <https://onco.cc/terms/lymphoma-classification-2022/>, <https://onco.cc/terms/lymphoma-b-versus-t-cell/>, <https://onco.cc/terms/lymphoma-indolent-versus-aggressive/>, <https://onco.cc/terms/lymphoma-nodal-versus-extranodal/>, <https://onco.cc/terms/lymphoma-tx-skin-directed-therapy/> ;
  onco:trials <https://onco.cc/trials/alcanza/>, <https://onco.cc/trials/mavoric/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-who-2022-lymphoid-alaggio-leukemia-2022/>, <https://onco.cc/key-papers/paper-mavoric-mogamulizumab-lancet-oncol-2018/>, <https://onco.cc/key-papers/paper-alcanza-brentuximab-vedotin-lancet-2017/>, <https://onco.cc/key-papers/paper-olsen-mycosis-fungoides-staging-blood-2007/> ;
  onco:pipeline <https://onco.cc/companies/soligenix/>, <https://onco.cc/drugs/mogamulizumab/> ;
  onco:standardOfCare <https://onco.cc/technologies/total-skin-electron-therapy/>, <https://onco.cc/technologies/superficial-radiotherapy/>, <https://onco.cc/drugs/bexarotene/>, <https://onco.cc/drugs/methoxsalen-ecp/>, <https://onco.cc/drugs/bexarotene/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/mogamulizumab/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/vorinostat/>, <https://onco.cc/drugs/romidepsin/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/technologies/allogeneic-hsct/> .